title: Sorafenib as an adjuvant therapy for resectable hepatocellular carcinoma: A single center experience.
abstract: OBJECTIVE
  Resectable hepatocellular carcinoma (HCC) is currently treated with surgical resection without any adjuvant therapy. We sought to assess the value of sorafenib as an adjuvant treatment in that clinical setting.
  
  
  METHODS
  Of a total of 30 patients, 16 underwent curative- intent liver resection for HCC and subsequently received adjuvant sorafenib, while 14 underwent surgery alone. Clinicopathological characteristics were analyzed and the impact of adjuvant sorafenib on overall survival (OS) was assessed.
  
  
  RESULTS
  The median follow up time was 38.2 months. The median patient age was 63.5 and 76.7% of them were male. The majority of patients had a solitary tumor (74.1%) with a median size of 7.75 cm. Five-year OS for the whole cohort was 60.2%. OS for patients who underwent only resection was 52.9 vs 68.1% for patients who underwent resection and received adjuvant sorafenib (p=0.19).
  
  
  CONCLUSIONS
  Sorafenib seems to be associated with an acceptable safety profile but does not confer any substantial clinical benefit in terms of survival in HCC patients who have undergone curative-intent liver resection.
authors.affiliation: 2nd Department of Propaedeutic Surgery, Laiko General Hospital, School of Medicine, University of Athens, Athens, Greece.
authors.forename: Efstathios A
authors.initials: EA
authors.lastname: Antoniou
authors.forename: Georgios A
authors.initials: GA
authors.lastname: Margonis
authors.forename: Neda
authors.initials: N
authors.lastname: Amini
authors.forename: Maria
authors.initials: M
authors.lastname: Anastasiou
authors.forename: Anastasios
authors.initials: A
authors.lastname: Angelou
authors.forename: Yuhree
authors.initials: Y
authors.lastname: Kim
authors.forename: Grigorios
authors.initials: G
authors.lastname: Kouraklis
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006115:Greece; D006498:Hepatectomy; D006801:Humans; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D000077157:Sorafenib; D013997:Time Factors; D016896:Treatment Outcome; D047368:Tumor Burden
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib